NCT06034002 2026-03-16
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
Clinical Trials
8 trialsNCT06150157 2026-03-16
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06120140 2026-03-13
COCOON
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT05936359 2026-02-10
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT06397313 2025-09-23
POTAMI-61
Ryvu Therapeutics SA
Phase 2 Recruiting
NCT06225310 2025-01-16
KPT-IST-391
Oncotherapeutics
Phase 1 Recruiting
NCT06209606 2024-12-17
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Oncotherapeutics
Phase EARLY_PHASE1 Recruiting
NCT03110822 2023-11-01
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Oncotherapeutics
Phase 1 Recruiting